|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lutz JM, Francisci S, Mugno E, Usel M,
Pompe-Kirn V, Coebergh JW and Bieslka-Lasota M; EUROPREVAL Working
Group. Cancer prevalence in Central Europe: the EUROPREVAL Study.
Ann Oncol. 14:313–322. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Emons G, Fleckenstein G, Hinney B,
Huschmand A and Heyl W: Hormonal interactions in endometrial
cancer. Endocr Relat Cancer. 7:227–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cirisano FD Jr, Robboy SJ, Dodge RK,
Bentley RC, Krigman HR, Synan IS, Soper JT and Clarke-Pearson DL:
The outcome of stage I–II clinically and surgically staged
papillary serous and clear cell endometrial cancers when compared
with endometrioid carcinoma. Gynecol Oncol. 77:55–65. 2000.
|
|
5
|
Ito K, Utsunomiya H, Yaegashi N and Sasano
H: Biological roles of estrogen and progesterone in human
endometrial carcinoma - new developments in potential endocrine
therapy for endometrial cancer. Endocr J. 54:667–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gründker C, Günthert AR and Emons G:
Hormonal heterogeneity of endometrial cancer. Adv Exp Med Biol.
630:166–188. 2008.
|
|
7
|
Armstrong AJ, Hurd WW, Elguero S, Barker
NM and Zanotti KM: Diagnosis and management of endometrial
hyperplasia. J Minim Invasive Gynecol. 19:562–571. 2012. View Article : Google Scholar
|
|
8
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012. View Article : Google Scholar
|
|
9
|
Lax S: Precursor lesions of endometrial
carcinoma: diagnostic approach and molecular pathology. Pathologe.
32(Suppl 2): S255–S264. 2011.(In German).
|
|
10
|
Tao MH and Freudenheim JL: DNA methylation
in endometrial cancer. Epigenetics. 5:491–498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reinhold WC, Reimers MA, Lorenzi P, Ho J,
Shankavaram UT, Ziegler MS, Bussey KJ, Nishizuka S, Ikediobi O,
Pommier YG and Weinstein JN: Multifactorial regulation of
E-cadherin expression: an integrative study. Mol Cancer Ther.
9:1–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fanelli F and Raimondi F: Nucleotide
binding affects intrinsic dynamics and structural communication in
Ras GTPases. Curr Pharm Des. 19:4214–4225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang J and Pervaiz S: Crosstalk between
Bcl-2 family and Ras family small GTPases: potential cell fate
regulation? Front Oncol. 2:2062012.PubMed/NCBI
|
|
14
|
Di Domenico M, Santoro A, Ricciardi C,
Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito
S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P,
Guida M, De Rosa G, Abbruzzese A, Caraglia M and Pannone G:
Epigenetic fingerprint in endometrial carcinogenesis: the
hypothesis of a uterine field cancerization. Cancer Biol Ther.
12:447–457. 2011.PubMed/NCBI
|
|
15
|
Holliday R: The inheritance of epigenetic
defects. Science. 238:163–170. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jones PA: DNA methylation errors and
cancer. Cancer Res. 56:2463–2467. 1996.PubMed/NCBI
|
|
17
|
Holliday R: DNA methylation and epigenetic
defects in carcinogenesis. Mutat Res. 181:215–217. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones A, Lechner M, Fourkala EO,
Kristeleit R and Widschwendter M: Emerging promise of epigenetics
and DNA methylation for the diagnosis and management of women’s
cancers. Epigenomics. 2:9–38. 2010.PubMed/NCBI
|
|
19
|
Banno K, Kisu I, Yanokura M, Masuda K,
Ueki A, Kobayashi Y, Susumu N and Aoki D: Epigenetics and genetics
in endometrial cancer: new carcinogenic mechanisms and relationship
with clinical practice. Epigenomics. 4:147–162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yi TZ, Li J, Han X, Guo J, Qu Q, Guo L,
Sun HD and Tan WH: DNMT inhibitors and HDAC inhibitors regulate
E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro
and in vivo. Chemotherapy. 58:19–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lasabova Z, Tilandyova P, Kajo K, Zubor P,
Burjanivova T, Danko J and Plank L: Hypermethylation of the GSTP1
promoter region in breast cancer is associated with prognostic
clinicopathological parameters. Neoplasma. 57:35–40. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Culbova M, Lasabova Z, Stanclova A,
Tilandyova P, Zubor P, Fiolka R, Danko J and Visnovsky J:
Methylation of selected tumor-suppressor genes in benign and
malignant ovarian tumors. Ceska Gynekol. 76:274–279. 2011.(In
Slovak).
|
|
23
|
Jha AK, Nikbakht M, Jain V, Capalash N and
Kaur J: p16(INK4a) and p15(INK4b) gene
promoter methylation in cervical cancer patients. Oncol Lett.
3:1331–1335. 2012.
|
|
24
|
Silverberg SG, Kurman RJ, Nogales F,
Mutter GL, Kubik-Huch RA and Tavassoli FA: Epithelial tumours and
related lesions. Pathology and Genetics of Tumours of the Breast
and Female Genital Organs. Tavassoli FA and DeVilee P: IARC Press;
Lyon: pp. 221–232. 2003
|
|
25
|
Zaino RJ, Kurman RJ, Diana KL and Morrow
CP: The utility of the revised International Federation of
Gynecology and Obstetrics histologic grading of endometrial
adenocarcinoma using a defined nuclear grading system. A
Gynecologic Oncology Group study. Cancer. 75:81–86. 1995.
View Article : Google Scholar
|
|
26
|
Zaino RJ: FIGO staging of endometrial
adenocarcinoma: a critical review and proposal. Int J Gynecol
Pathol. 28:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Herman JG, Graff JR, Myohanen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: a novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
House MG, Guo MZ, Iacobuzio-Donahue C and
Herman JG: Molecular progression of promoter methylation in
intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
Carcinogenesis. 24:193–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu
JC, Yan PS and Huang TH: Double RNA interference of DNMT3b and
DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res.
63:6110–6115. 2003.PubMed/NCBI
|
|
31
|
Shen WJ, Dai DQ, Teng Y and Liu HB:
Regulation of demethylation and re-expression of RASSF1A gene in
gastric cancer cell lines by combined treatment of 5-Aza-CdR and
NaB. World J Gastroenterol. 14:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heichman KA and Warren JD: DNA methylation
biomarkers and their utility for solid cancer diagnostics. Clin
Chem Lab Med. 50:1707–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hatzimichael E and Crook T: Cancer
epigenetics: new therapies and new challenges. J Drug Deliv.
13:5293122013.PubMed/NCBI
|
|
34
|
Pallarés J, Velasco A, Eritja N, Santacana
M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J and
Matias-Guiu X: Promoter hypermethylation and reduced expression of
RASSF1A are frequent molecular alterations of endometrial
carcinoma. Mod Pathol. 21:691–699. 2008.
|
|
35
|
Fiegl H, Gattringer C, Widschwendter A,
Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Müller HM,
Mueller-Holzner E, Marth C and Widschwendter M: Methylated DNA
collected by tampons - a new tool to detect endometrial cancer.
Cancer Epidemiol Biomarkers Prev. 13:882–888. 2004.PubMed/NCBI
|
|
36
|
Kang S, Kim JW, Kang GH, Lee S, Park NH,
Song YS, Park SY, Kang SB and Lee HP: Comparison of DNA
hypermethylation patterns in different types of uterine cancer:
cervical squamous cell carcinoma, cervical adenocarcinoma and
endometrial adenocarcinoma. Int J Cancer. 118:2168–2171. 2006.
View Article : Google Scholar
|
|
37
|
Pijnenborg JM, Kisters N, van Engeland M,
Dunselman GA, de Haan J, de Goeij AF and Groothuis PG: APC,
beta-catenin, and E-cadherin and the development of recurrent
endometrial carcinoma. Int J Gynecol Cancer. 14:947–956. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arafa M, Kridelka F, Mathias V,
Vanbellinghen JF, Renard I, Foidart JM, Boniver J and Delvenne P:
High frequency of RASSF1A and RARb2 gene promoter
methylation in morphologically normal endometrium adjacent to
endometrioid adenocarcinoma. Histopathology. 53:525–532. 2008.
|
|
39
|
Liao X, Siu MK, Chan KY, Wong ES, Ngan HY,
Chan QK, Li AS, Khoo US and Cheung AN: Hypermethylation of RAS
effector-related genes and DNA methyltransferase 1 expression in
endometrial carcinogenesis. Int J Cancer. 123:296–302. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Seeber LM, Zweemer RP, Marchionni L,
Massuger LF, Smit VT, van Baal WM, Verheijen RH and van Diest PJ:
Methylation profiles of endometrioid and serous endometrial
cancers. Endocr Relat Cancer. 17:663–673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pijnenborg JM, Dam-de Veen GC, Kisters N,
Delvoux B, van Engeland M, Herman JG and Groothuis PG:
RASSF1A methylation and K-ras and B-raf
mutations and recurrent endometrial cancer. Ann Oncol. 18:491–497.
2007. View Article : Google Scholar
|
|
42
|
Jo H, Kim JW, Kang GH, Park NH, Song YS,
Kang SB and Lee HP: Association of promoter hypermethylation of the
RASSF1A gene with prognostic parameters in endometrial cancer.
Oncol Res. 16:205–209. 2006.PubMed/NCBI
|
|
43
|
Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim
HS, Seo SS, Park SY, Sidransky D and Dong SM: RASSF1A
hypermethylation and its inverse correlation with BRAF
and/or KRAS mutations in MSI-associated endometrial
carcinoma. Int J Cancer. 119:1316–1321. 2006. View Article : Google Scholar
|
|
44
|
Zhang YQ, Mao XY, Ma XL, Zhang M and Sheng
N: Effects and mechanisms of 5-aza-2′-deoxycytidine on endometrial
cancer cell. Zhonghua Fu Chan Ke Za Zhi. 44:861–864. 2009.(In
Chinese).
|
|
45
|
Yu MY, Tong JH, Chan PK, Lee TL, Chan MW,
Chan AW, Lo KW and To KF: Hypermethylation of the tumor suppressor
gene RASSFIA and frequent concomitant loss of heterozygosity
at 3p21 in cervical cancers. Int J Cancer. 105:204–209.
2003.PubMed/NCBI
|
|
46
|
Moreno-Bueno G, Hardisson D, Sarrió D,
Sánchez C, Cassia R, Prat J, Herman JG, Esteller M, Matías-Guiu X
and Palacios J: Abnormalities of E- and P-cadherin and catenin (β-,
γ-catenin, and p120ctn) expression in endometrial cancer
and endometrial atypical hyperplasia. J Pathol. 199:471–478.
2003.PubMed/NCBI
|
|
47
|
Saito T, Nishimura M, Yamasaki H and Kudo
R: Hypermethylation in promoter region of E-cadherin gene is
associated with tumor dedifferentiation and myometrial invasion in
endometrial carcinoma. Cancer. 97:1002–1009. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Banno K, Yanokura M, Susumu N, Kawaguchi
M, Hirao N, Hirasawa A, Tsukazaki K and Aoki D: Relationship of the
aberrant DNA hypermethylation of cancer-related genes with
carcinogenesis of endometrial cancer. Oncol Rep. 16:1189–1196.
2006.PubMed/NCBI
|
|
49
|
Yi TZ, Guo J, Zhou L, Chen X, Mi RR, Qu
QX, Zheng JH and Zhai L: Prognostic value of E-cadherin expression
and CDH1 promoter methylation in patients with endometrial
carcinoma. Cancer Invest. 29:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Graff JR, Gabrielson E, Fujii H, Baylin SB
and Herman JG: Methylation patterns of the E-cadherin 5′ CpG island
are unstable and reflect the dynamic, heterogeneous loss of
E-cadherin expression during metastatic progression. J Biol Chem.
275:2727–2732. 2000.
|
|
51
|
Moreno-Bueno G, Hardisson D, Sánchez C,
Sarrió D, Cassia R, García-Rostán G, Prat J, Guo M, Herman JG,
Matías-Guiu X, Esteller M and Palacios J: Abnormalities of the
APC/β-catenin pathway in endometrial cancer. Oncogene.
21:7981–7990. 2002.
|
|
52
|
Yoshiura K, Kanai Y, Ochiai A, Shimoyama
Y, Sugimura T and Hirohashi S: Silencing of the E-cadherin
invasion-suppressor gene by CpG methylation in human carcinomas.
Proc Natl Acad Sci USA. 92:7416–7419. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Takai N, Desmond JC, Kumagai T, Gui D,
Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone
deacetylase inhibitors have a profound antigrowth activity in
endometrial cancer cells. Clin Cancer Res. 10:1141–1149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hirohashi S: Inactivation of the
E-cadherin-mediated cell adhesion system in human cancers. Am J
Pathol. 153:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chan QK, Khoo US, Chan KY, Ngan HY, Li SS,
Chiu PM, Man LS, Ip PP, Xue WC and Cheung AN: Promoter methylation
and differential expression of π-class glutathione S-transferase in
endometrial carcinoma. J Mol Diagn. 7:8–16. 2005.
|
|
56
|
Kim GE, Kweon SS, Lee JS, Lee JH, Nam JH
and Choi C: Quantitative assessment of DNA methylation for the
detection of cervical and endometrial adenocarcinomas in
liquid-based cytology specimens. Anal Quant Cytol Histol.
34:195–203. 2012.PubMed/NCBI
|
|
57
|
Nieminen TT, Gylling A, Abdel-Rahman WM,
Nuorva K, Aarnio M, Renkonen-Sinisalo L, Järvinen HJ, Mecklin JP,
Bützow R and Peltomäki P: Molecular analysis of endometrial
tumorigenesis: importance of complex hyperplasia regardless of
atypia. Clin Cancer Res. 15:5772–5783. 2009. View Article : Google Scholar : PubMed/NCBI
|
